U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07497386) titled 'A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer' on March 19.
Brief Summary: The study is designed to compare the efficacy and safety of different dose groups of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in patients with HR-positive, HER2-low unresectable locally recurrent/metastatic breast cancer. It will also exploratively evaluate the pharmacokinetic profile and immunogenicity of Trastuzumab Rezetecan.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Unresectable Locally Recurrent Breast Cancer
Unresectable Locally Metastatic Breast Cancer
Intervention:
D...